Nicotine regulates PCSK9 expression in HepG2 cells through Raf/MEK/ERK signaling pathway
陆军军医大学学报, 2023 Objective To investigate the effect of nicotine (NIC) on the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) and its molecular mechanism.
ZHOU Lin +4 more
doaj +1 more source
Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels. [PDF]
Rev Cardiovasc MedBackground: A meta-analysis was conducted to determine whether the cardiovascular mortality and lipid-lowering effects of alirocumab and evolocumab are influenced by various baseline low-density lipoprotein cholesterol (LDL-C) levels. Methods: We searched for literature published before June 2023.
Ma H, Ma W, Liu Y, Chen L, Ding P.
europepmc +4 more sources
Ezetimibe therapy: mechanism of action and clinical update. [PDF]
, 2012 The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events.
Dayspring, Thomas D +2 more
core +1 more source
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis [PDF]
, 2012 ObjectivesThe purpose of this study was to estimate the effect of long-term exposure to lower plasma low-density lipoprotein cholesterol (LDL-C) on the risk of coronary heart disease (CHD).BackgroundLDL-C is causally related to the risk of CHD.
Ference, Brian A. +9 more
core +2 more sources
Serum level of monocyte chemotactic protein 1, N-terminal brain natural peptide in patients with coronary heart disease after nutritional changes [PDF]
Journal of Medical BiochemistryBackground: Coronary heart disease (CHD) is a leading cause of morbidity among elderly populations, with inflammation and cardiac dysfunction indicated by elevated MCP-1 and NT-proBNP levels.
Ding Yueyou +3 more
doaj +1 more source
Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia [PDF]
Journal of Clinical and Diagnostic Research, 2014 Introduction: Statins (or HMG-CoA reductase inhibitors) have become drug of choice for raised Low-Density Lipoprotein Cholesterol (LDL-C) in treating.
Canna Jagdish Ghia +4 more
doaj +1 more source
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. [PDF]
, 2018 Large-scale deep-coverage whole-genome sequencing (WGS) is now feasible and offers potential advantages for locus discovery. We perform WGS in 16,324 participants from four ancestries at mean depth >29X and analyze genotypes with four quantitative ...
Abecasis, Goncalo +36 more
core +2 more sources
The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. [PDF]
, 2020 In pharmacogenomic studies of quantitative change, any association between genetic variants and the pretreatment (baseline) measurement can bias the estimate of effect between those variants and drug response.
Haldar, Tanushree +8 more
core +2 more sources
Effect of Carrageenans on Vegetable Jelly in Humans with Hypercholesterolemia
Marine Drugs, 2019 Changes in lipid profile constitute the main risk factor for cardiovascular diseases. Algae extracted carrageenans are long-chain polysaccharides and their ability to form gels provides for the formation of vegetable jelly.
Ana Valado +7 more
doaj +1 more source
Fatigued with Friedewald: why isn't everyone onboard yet with the new LDL-C equations? [PDF]
Frontiers in Cardiovascular MedicineMadhusudhanan Narasimhan +6 more
doaj +2 more sources